The three biggest Big Pharma "blockbuster" medicines of all time target high cholesterol (Lipitor), inflammatory diseases (Humira), and digestive afflictions (Nexium) and have pulled in a combined $350 billion – and counting.
But what about people suffering from rare diseases like cystic fibrosis, pancreatic cancer, and so on?
Here in America, Washington understands the need for these "orphan drugs" targeting rare diseases, which is why the "Orphan Drug Act of 1983" offers a seven-year window of tax reductions and the exclusive right to market a drug for a particular rare disease.
To date, more than 600 orphan drugs have been approved by the FDA.
And the global market for orphan drugs targeting rare diseases is growing at double the rate of the non-orphan market.
But more needs to be done. And that "more" will create a massive investment portal – provided you pick the best-positioned companies.